TuesdayJun 26, 2012 12:57 pm

Year-End 1500 for S&P 500? What It Will Take to Crack March Highs

A handful of four primary vectors were drawn up today by the chief investment strategist over at Wells Capital Management, Jim Paulsen, in an interview on his 1,500 target for the S&P 500. In an opening salvo against market crisis neuroses, Paulsen pegged Europe as no longer being a crisis in any proper sense, as the cyclical nature he predicts will be evinced once again at the European Summit this week. The argument is that Europe is basically a "chronic problem.” Europe is a problem that will be with us for decades, but not one that will derail a global…

Continue Reading

TuesdayJun 26, 2012 8:45 am

Discover Hidden Trading Opportunities with TinyGems

It turns out, well-run small companies are not inherently risky. It’s one of the best kept secrets on Wall Street! TinyGem’s Hidden Gems Newsletter features undiscovered, undervalued companies on a regular basis. Each month, subsribers receive a summary of the team’s research. If you would like sign up for the TinyGems Monthly Newsletter and discover new, undiscovered small-cap companies, visit www.tinygems.net Let us hear your thoughts below:

Continue Reading

TuesdayJun 26, 2012 8:38 am

Curis, Inc. (CRIS) Announces Clinical Cancer Research Journal to Publish CUDC-907 Data

Curis, a drug development company focused on developing proprietary targeted medicines for cancer treatment, announced today an article regarding CUDC-907 has been published in the journal Clinical Cancer Research. CUDC-907 is an orally-available small molecule drug candidate under development by Curis, and it is designed to simultaneously inhibit PI3K and HDAC. Several members of Curis’ scientific team authored the article, titled "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase (HDAC) activity and phosphatidylinositol 3-kinase (PI3K) signaling.” The article will be published in the print version of the journal in the near future. "We are encouraged by…

Continue Reading

MondayJun 25, 2012 2:59 pm

OXIS International, Inc. (OXIS) Announces Online Commercial Availability of Proprietary Joint Health Product

OXIS International, developer of technologies and products that address oxidative stress/inflammation stemming from free radical and reactive oxygen species (ROS), today announced the international commercial launch of its proprietary joint health product, ErgoFlex™, available online. Preventive Medicine recently published a study that demonstrated ErgoFlex’s efficacy in reducing pain and increasing range of motion in people who suffer from joint pain. The active ingredient in ErgoFlex is EGT, the only antioxidant with the ability to be delivered through the cell membrane and into the energy producing area of the cell. The antioxidant is so effective that when other powerful antioxidants are…

Continue Reading

MondayJun 25, 2012 2:50 pm

Synthesis Energy Systems, Inc. (SYMX) Tests of Turkish Lignite Coals a Success, Syngas Plants Planned

Synthesis Energy Systems, whose proprietary U-GAS® clean energy (fluidized bed gasification) technology, equipment, and engineering services have rapidly gained acclaim in the energy sector for helping turn low-cost feedstock/biomass into energy and chemical products, reported positive lab-scale output data today, with the completion of testing on three Turkish lignite coal targets earmarked for clean coal power generation projects. Under development by one of Turkey’s largest independent power project (IPP) developers, Tuten Ltd., the clean coal infrastructure development is being sponsored by a major Turkish utility company intent on modernizing their production footprint. Also part of the project will be Slovakian…

Continue Reading

MondayJun 25, 2012 9:34 am

EMCORE Corp. (EMKR) Announces New Opticomm-EMCORE NV Series JPEG 2000 Products

EMCORE recently announced the introduction of Opticomm-EMCORE NV Series JPEG 2000 products, which provide optimum quality and lowest latency real-time HD video distribution over Internet protocol (IP) to the broadcast and professional audio/visual markets. Using IP infrastructures, the NV Series sends out high-resolution 3G HD, HDMI, or DVI signals to HD monitors in one or many locations. This technology enables distribution of HD digital content from multiple sources to almost limitless displays of LAN. Having very low latency is a critical aspect of the system when video is transmitting directly from a live site to an editing studio. In the…

Continue Reading

FridayJun 22, 2012 3:18 pm

FDA Approves Cellceutix Corp. (CTIX) Proposed Phase I Clinical Trial for Anti-Cancer Compound

Biopharm company Cellceutix today said the U.S. Food and Drug Administration (FDA) has reviewed the company's Investigational New Drug (IND) application for its novel anti-cancer compound Kevetrin™ and has approved the company’s advancement to phase I clinical trial. The phase 1 clinical trial for Kevetrin will take place at Harvard Cancer Center's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center. The company also announced that both the Institutional Review Board and the Scientific Review Committee have approved the protocol for the clinical trial. Cellceutix said it will provide details on the commencement of the clinical trials to shareholders…

Continue Reading

FridayJun 22, 2012 3:16 pm

Great Wall Builders Ltd. (GWBU) Distributor Inks Distribution Contract for FEED Units in Slovenia

Great Wall Builders, dba "Start Technologies Europe," along with the company’s exclusive European distributor NESS Tech GmbH, today announced the appointment of TE.SIS d.o.o, as its agent for the Slovenian market. The company on May 18, 2012, reported NESS Tech GmbH as the exclusive GWBU agent for the European Union and other select European markets, per a five-year agreement. The distribution contract between NESS Tech and TE.SIS d.o.o. calls for a minimum wholesale purchase of EUR750,000 in Start Fuel Efficiency and Emission Device (FEED) units in the first 12 months in addition to the requirement to increase the minimum purchase…

Continue Reading

FridayJun 22, 2012 3:15 pm

Accelr8 Technology Corp. (AXK) Announces Results of Two Studies and Receives Approval to Present a New Blood Study

Accelr8 Technology today announced the promising results of two studies that it presented at the 112th annual General Meeting of the American Society for Microbiology. The first study involved the use of Accelr8’s BACcel™ rapid automated diagnostic system with positive blood cultures to identify a significant, complex multi-drug resistance expression type know as “ESBL.” The study showed that the system was capable of maintaining 100% sensitivity and 94% specificity while decreasing time to result by 1-2 days over the best standard method used today. Identifying ESBL resistance has become an incredibly important endeavor, as ESBL resistance has spread across the…

Continue Reading

FridayJun 22, 2012 1:31 pm

Gold Standard Ventures Corp. (GSV) Nails Down $20M Public Offering, Plans to Develop Flagship Nevada Gold Project

Gold Standard Ventures has relentlessly pursued a very clear strategy since the company’s inception to go after district-scale lockdown of gold mineralized acreage in Nevada and issued a report today detailing their latest effort to muscle out gold production, with the move to sell 10M shares of GSV common stock, raising proceeds that will fund exploration/development. Emphasis will be placed on developing the company’s flagship project in Elko County, the some 21k-acre Railroad Project (adjacent to Newmont Mining’s Rain/Emigrant mines), which features rich Carlin-type mineralization in collapsed breccias. In addition, ancillary drilling, exploration, and other such efforts, will benefit from…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered